HU196962B - Process for producing amlodipin-bezilate - Google Patents
Process for producing amlodipin-bezilate Download PDFInfo
- Publication number
- HU196962B HU196962B HU871450A HU145087A HU196962B HU 196962 B HU196962 B HU 196962B HU 871450 A HU871450 A HU 871450A HU 145087 A HU145087 A HU 145087A HU 196962 B HU196962 B HU 196962B
- Authority
- HU
- Hungary
- Prior art keywords
- priority
- amlodipine
- besylate salt
- amlodipine besylate
- salt
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 23
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical class [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims abstract description 15
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical class CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical class OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 claims description 38
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 33
- 238000002360 preparation method Methods 0.000 claims description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 229920002261 Corn starch Polymers 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 4
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 claims description 4
- 229940062672 calcium dihydrogen phosphate Drugs 0.000 claims description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 4
- 239000012442 inert solvent Substances 0.000 claims description 4
- 235000019691 monocalcium phosphate Nutrition 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 4
- 239000008109 sodium starch glycolate Substances 0.000 claims description 4
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 4
- 239000008215 water for injection Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 238000007911 parenteral administration Methods 0.000 claims description 3
- 150000003863 ammonium salts Chemical class 0.000 claims description 2
- 239000007963 capsule composition Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims 6
- 238000007873 sieving Methods 0.000 claims 5
- 229940057948 magnesium stearate Drugs 0.000 claims 3
- 235000019759 Maize starch Nutrition 0.000 claims 2
- 239000008135 aqueous vehicle Substances 0.000 claims 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims 1
- 235000019700 dicalcium phosphate Nutrition 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 abstract description 29
- 229960000528 amlodipine Drugs 0.000 abstract description 16
- 230000002253 anti-ischaemic effect Effects 0.000 abstract description 2
- 229940030600 antihypertensive agent Drugs 0.000 abstract description 2
- 239000002220 antihypertensive agent Substances 0.000 abstract description 2
- 229960004005 amlodipine besylate Drugs 0.000 description 10
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 8
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 7
- 238000009472 formulation Methods 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 150000002688 maleic acid derivatives Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- -1 2-aminoethoxy Chemical group 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- 229950004221 besilate Drugs 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- BLUNNZYDUZHPAD-UHFFFAOYSA-N 4-methylbenzenesulfonic acid;dihydrate Chemical compound O.O.CC1=CC=C(S(O)(=O)=O)C=C1 BLUNNZYDUZHPAD-UHFFFAOYSA-N 0.000 description 1
- QPIFNZMAHNRKMM-UHFFFAOYSA-N C(C)(=O)O.C(C=C/C(=O)O)(=O)O.C(C=1C(O)=CC=CC1)(=O)O.C(CCC(=O)O)(=O)O.S(=O)(=O)(O)C1=CC=C(C)C=C1.S(C)(=O)(=O)O Chemical compound C(C)(=O)O.C(C=C/C(=O)O)(=O)O.C(C=1C(O)=CC=CC1)(=O)O.C(CCC(=O)O)(=O)O.S(=O)(=O)(O)C1=CC=C(C)C=C1.S(C)(=O)(=O)O QPIFNZMAHNRKMM-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- WWLOCCUNZXBJFR-UHFFFAOYSA-N azanium;benzenesulfonate Chemical compound [NH4+].[O-]S(=O)(=O)C1=CC=CC=C1 WWLOCCUNZXBJFR-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WWIWLTSSHDKOKO-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1.OS(=O)(=O)C1=CC=CC=C1 WWIWLTSSHDKOKO-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- GXHMMDRXHUIUMN-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O GXHMMDRXHUIUMN-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000004682 monohydrates Chemical group 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000009527 percussion Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB868608335A GB8608335D0 (en) | 1986-04-04 | 1986-04-04 | Pharmaceutically acceptable salts |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUT43821A HUT43821A (en) | 1987-12-28 |
| HU196962B true HU196962B (en) | 1989-02-28 |
Family
ID=10595731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU871450A HU196962B (en) | 1986-04-04 | 1987-04-03 | Process for producing amlodipin-bezilate |
Country Status (47)
Families Citing this family (172)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5270323A (en) * | 1990-05-31 | 1993-12-14 | Pfizer Inc. | Method of treating impotence |
| EP1013275A3 (en) * | 1991-11-26 | 2001-01-10 | Sepracor, Inc. | Method and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine |
| US6057344A (en) | 1991-11-26 | 2000-05-02 | Sepracor, Inc. | Methods for treating hypertension, and angina using optically pure (-) amlodipine |
| US6162802A (en) * | 1992-03-10 | 2000-12-19 | Papa; Joseph | Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor |
| AT399718B (de) * | 1992-04-16 | 1995-07-25 | Lek Tovarna Farmacevtskih | Inklusionskomplexe von optisch aktiven und racemischen 1,4-dihydropyridinen mit methyl-beta- cyclodextrin oder anderen cyclodextrinderivaten, ein verfahren zur herstellung von optisch aktiven dihydropyridinen und deren inklusionskomplexen und diese komplexe enthaltende pharmazeutische formulierungen |
| SI9200344B (sl) * | 1992-11-26 | 1998-06-30 | Lek, | Postopek za pripravo amlodipin benzensulfonata |
| US5389654A (en) * | 1992-11-26 | 1995-02-14 | Lek, Tovarna, Farmacevtskih In Kemicnih . . . | 3-ethyl 5-methyl(±)2-[2-(N-tritylamino)ethoxymethyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-6-methyl-3,5-pyridinedicarboxylate |
| USRE39384E1 (en) | 1993-09-01 | 2006-11-07 | Smithkline Beecham P.L.C. | Substituted thiazolidinedione derivatives |
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US6245787B1 (en) | 1995-03-16 | 2001-06-12 | Pfizer Inc. | Composition containing amlodipine or a pharmaceutically acceptable salt thereof, and an ACE inhibitor |
| HU221810B1 (hu) * | 1997-08-12 | 2003-01-28 | EGIS Gyógyszergyár Rt. | Eljárás amlodipin-bezilát előállítására és az eljárás intermedierjei |
| GT199800127A (es) * | 1997-08-29 | 2000-02-01 | Combinaciones terapeuticas. | |
| WO1999018957A1 (en) * | 1998-03-26 | 1999-04-22 | Reddy-Cheminor, Inc. | Stable pharmaceutical composition containing amlodipine besylate and atenolol |
| RU2188636C2 (ru) * | 1998-03-26 | 2002-09-10 | Др. Редди'С Лабораторис Лтд. | Стабильный фармацевтический препарат, содержащий амлодипина безилат и атенолол |
| PL189666B1 (pl) * | 1998-04-09 | 2005-09-30 | Adamed Sp Z Oo | Sposób otrzymywania benzenosulfonianu amlodypiny |
| AU753486B2 (en) | 1998-07-10 | 2002-10-17 | Novartis Ag | Method of treatment and pharmaceutical composition |
| US20070072828A1 (en) * | 1998-07-24 | 2007-03-29 | Yoo Seo H | Bile preparations for colorectal disorders |
| US7772220B2 (en) * | 2004-10-15 | 2010-08-10 | Seo Hong Yoo | Methods and compositions for reducing toxicity of a pharmaceutical compound |
| US20050158408A1 (en) * | 1998-07-24 | 2005-07-21 | Yoo Seo H. | Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof |
| US7303768B2 (en) * | 1998-07-24 | 2007-12-04 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
| UA33033A (uk) * | 1998-10-16 | 2001-02-15 | Др.Редіс Леборетрис Лтд | Спосіб одержання безилату амлодипіну |
| US7129265B2 (en) * | 1999-04-23 | 2006-10-31 | Mason R Preston | Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy |
| RU2142942C1 (ru) * | 1999-04-28 | 1999-12-20 | Дж. Б.Кемикалс энд Фармасьютикалс Лтд. | Способ получения монобензолсульфоната 3-этил-5-метилового эфира 2-[(2-аминоэтокси)метил]-4-(2-хлорфенил)-1,4-дигидро-6-метил-3,5-пиридинди карбоновой кислоты |
| HN2000000050A (es) | 1999-05-27 | 2001-02-02 | Pfizer Prod Inc | Sal mutua de amlodipino y atorvastatina |
| ES2220426T3 (es) | 1999-05-27 | 2004-12-16 | Pfizer Products Inc. | Profarmacos mutuos de amlodipino y atorvastatina. |
| RU2161156C1 (ru) * | 1999-06-01 | 2000-12-27 | Джи.Б.Кемикалс Энд Фармасьютикалс Лтд | Способ получения 3-этил-5-метиловый эфир 2-[2-(n-фталимидо)-этоксиметил]-4-(2-хлорфенил)-1,4-дигидро-6-метил-3,5- пиридиндикарбоновой кислоты |
| UA72768C2 (en) * | 1999-07-05 | 2005-04-15 | Richter Gedeon Vegyeszet | A method for obtaining amilodipine benzenesulphonate |
| RU2146672C1 (ru) * | 1999-10-13 | 2000-03-20 | Др.Редди'С Лабораторис Лтд. | Способ получения 3-этил-5-метил(±)2[2-аминоэтокси)-метил]-4-(2-хлорфенил)-1,4-дигидро- 6-метил-3,5-пиридиндикарбоксилат монобензолсульфоната |
| US6521647B2 (en) | 2000-04-04 | 2003-02-18 | Pfizer Inc. | Treatment of renal disorders |
| US6835742B2 (en) | 2000-08-04 | 2004-12-28 | R. Preston Mason | Synergistic effect of amlodipine and atorvastatin on cholesterol crystal formation inhibition and aortic endothelial cell nitric oxide release |
| US6737430B2 (en) | 2000-11-09 | 2004-05-18 | Pfizer, Inc. | Mutual prodrug of amlodipine and atorvastatin |
| GB0027410D0 (en) * | 2000-11-09 | 2000-12-27 | Pfizer Ltd | Mutual prodrug of amlodipine and atorvastatin |
| GB2371862B (en) * | 2000-12-29 | 2004-07-14 | Bioorg Bv | Reference standards for determining the purity or stability of amlodipine maleate and processes therefor |
| MXPA03005882A (es) | 2000-12-29 | 2005-04-19 | Pfizer Ltd | Derivado amida de amlodipina. |
| BR0116554A (pt) | 2000-12-29 | 2004-02-03 | Pfizer Ltd | Composto, composição farmacêutica para o tratamento da angina ou hipertensão, processo, processo para o tratamento ou prevenção da angina ou hipertensão, composição do ingrediente farmaceuticamente ativo e composição farmacêutica para o tratamento ou prevenção da angina ou hipertensão |
| US6653481B2 (en) | 2000-12-29 | 2003-11-25 | Synthon Bv | Process for making amlodipine |
| AT5874U1 (de) | 2000-12-29 | 2003-01-27 | Bioorg Bv | Pharmazeutische zubereitungen enthaltend amlodipinmaleat |
| US7335380B2 (en) | 2000-12-29 | 2008-02-26 | Synthon Ip Inc. | Amlodipine free base |
| CA2433181C (en) | 2000-12-29 | 2005-11-22 | Pfizer Limited | Amlodipine hemifumarate |
| MXPA03005884A (es) | 2000-12-29 | 2005-04-08 | Pfizer Ltd | Hemimaleato de amlodipina. |
| MXPA03005886A (es) | 2000-12-29 | 2005-04-19 | Pfizer Ltd | Derivado de aspartato de amlodipina como antagonista del canal de calcio. |
| PL362660A1 (en) | 2000-12-29 | 2004-11-02 | Pfizer Limited | Process for making amlodipine maleate |
| EP1221438B1 (de) * | 2001-01-09 | 2007-03-14 | Siegfried Generics International AG | Salze von Amlodipin-Mesylat |
| GB0103046D0 (en) | 2001-02-07 | 2001-03-21 | Novartis Ag | Organic Compounds |
| KR100452491B1 (ko) * | 2001-03-29 | 2004-10-12 | 한미약품 주식회사 | 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법 |
| US20030027848A1 (en) * | 2001-06-15 | 2003-02-06 | Anne Billotte | Stabilized formulations |
| EP1435954B1 (en) * | 2001-07-06 | 2010-01-13 | LEK Pharmaceuticals D.D. | A PROCESS FOR THE PREPARATION OF HIGHlLY PUREAMLODIPINE BENZENESULFONATE |
| US20030220310A1 (en) * | 2001-07-27 | 2003-11-27 | Schuh Joseph R. | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure |
| US6680334B2 (en) | 2001-08-28 | 2004-01-20 | Pfizer Inc | Crystalline material |
| US7544681B2 (en) | 2001-09-27 | 2009-06-09 | Ramot At Tel Aviv University Ltd. | Conjugated psychotropic drugs and uses thereof |
| US20040001886A1 (en) * | 2001-10-17 | 2004-01-01 | Dr. Reddy's Laboratories Limited | Stabilized pharmaceutical formulations containing amlodipine maleate |
| US6828339B2 (en) * | 2001-11-21 | 2004-12-07 | Synthon Bv | Amlodipine salt forms and processes for preparing them |
| HU226642B1 (en) * | 2001-12-17 | 2009-05-28 | Egis Gyogyszergyar Nyilvanosan | Amlodipine bezylate tablets having extended stability and process for producing the same |
| NL1019882C2 (nl) * | 2002-02-01 | 2003-08-04 | Synthon Licensing | Amlodipine vrije base. |
| EP2316468A1 (en) | 2002-02-22 | 2011-05-04 | Shire LLC | Delivery system and methods for protecting and administering dextroamphetamine |
| EP1499592A4 (en) * | 2002-04-13 | 2010-01-13 | Hanlim Pharmaceutical Co Ltd | AMLODIPINE NICOTINATE AND PROCESS FOR PREPARING THE SAME |
| CN100528241C (zh) | 2002-05-06 | 2009-08-19 | 恩多塞特公司 | 维生素-定向的显象剂 |
| EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| SI21233A (sl) * | 2002-05-31 | 2003-12-31 | LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. | Kristalni hidratni obliki amlodipin benzensulfonata visoke čistote, postopki za njuno pripravo in uporaba |
| US6699892B2 (en) | 2002-06-04 | 2004-03-02 | Yung Shin Pharmaceutical Industrial Co., Ltd. | Pharmaceutically acceptable salt of amlodipine and method of preparing the same |
| RU2221784C1 (ru) * | 2002-07-05 | 2004-01-20 | Марвел Лайфсайнсез Прайвит Лимитед | Способ получения бензолсульфоната амлодипина |
| KR100496436B1 (ko) * | 2002-07-30 | 2005-06-20 | 씨제이 주식회사 | 암로디핀의 유기산염 |
| KR20040011751A (ko) * | 2002-07-30 | 2004-02-11 | 씨제이 주식회사 | 암로디핀의 유기산염 |
| KR100538641B1 (ko) * | 2002-07-30 | 2005-12-22 | 씨제이 주식회사 | 암로디핀의 유기산염 |
| KR100462304B1 (ko) * | 2002-07-30 | 2004-12-17 | 씨제이 주식회사 | 암로디핀의 유기산염 |
| KR100467669B1 (ko) * | 2002-08-21 | 2005-01-24 | 씨제이 주식회사 | 암로디핀의 유기산염 |
| CA2496623C (en) | 2002-08-29 | 2008-02-12 | Taisho Pharmaceutical Co., Ltd. | Benzenesulfonate salts of 4-fluoro-2-cyanopyrrolidine derivatives |
| US6784297B2 (en) * | 2002-09-04 | 2004-08-31 | Kopran Limited | Process for the preparation of anti-ischemic and anti-hypertensive drug amlodipine besylate |
| US7279492B2 (en) | 2002-09-11 | 2007-10-09 | Hanlim Pharmaceutical Co., Ltd. | S-(−)-amlodipine nicotinate and process for the preparation thereof |
| WO2004026834A1 (en) * | 2002-09-19 | 2004-04-01 | Cj Corporation | Crystalline organic acid salt of amlodipine |
| US7166641B2 (en) * | 2002-10-02 | 2007-01-23 | Yung Shin Pharmaceutical Industrial Co., Ltd. | Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same |
| EP1407773A1 (en) * | 2002-10-08 | 2004-04-14 | Council of Scientific and Industrial Research | A process for the preparation of s (-) amlodipine salts |
| US20040072879A1 (en) * | 2002-10-10 | 2004-04-15 | Dr. Reddy's Laboratories Limited | Crystalline 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine maleate salt (Amlodipine) |
| AU2002368531A1 (en) * | 2002-12-30 | 2004-07-22 | Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. | Isolation of dihydropyridine derivative and preparation salts thereof |
| US20060128763A1 (en) | 2003-01-27 | 2006-06-15 | Moon Young H | Stable amorphous amlodipine camsylate, process for preparing same and composition for oral administration thereof |
| EP3045174A1 (en) * | 2003-01-31 | 2016-07-20 | Daiichi Sankyo Company, Limited | Medicine for prevention of and treatment for arteriosclerosis and hypertension |
| KR20040072363A (ko) * | 2003-02-12 | 2004-08-18 | 주식회사 대웅 | 신규한 암로디핀 사이클라메이트 염 및 그의 제조방법 |
| WO2004075825A2 (en) * | 2003-02-28 | 2004-09-10 | Ranbaxy Laboratories Limited | Dosage forms of amlodipine and processes for their preparation |
| GB2415696B (en) * | 2003-04-25 | 2007-06-20 | Cipla Ltd | Process for preparing amlodipine mesylate monohydrate |
| PL1618111T3 (pl) | 2003-04-25 | 2015-06-30 | Cadila Healthcare Ltd | Sole klopidogrelu i sposób wytwarzania |
| CA2523808A1 (en) * | 2003-05-16 | 2004-12-23 | Ambit Biosciences Corporation | Pyrrole compounds and uses thereof |
| US20050182125A1 (en) * | 2003-05-16 | 2005-08-18 | Ambit Biosciences Corporation | Pyrrole compounds and uses thereof |
| EP2319843B1 (en) | 2003-05-30 | 2013-04-03 | Ranbaxy Laboratories Limited | Substituted pyrrole derivatives and their use as HMG-CO inhibitors |
| RU2239433C1 (ru) * | 2003-06-09 | 2004-11-10 | Закрытое акционерное общество "Фармацевтическое предприятие "Оболенское" | Лекарственная форма, обладающая вазодилатирующим, антиангинальным, гипотензивным и спазмолитическим действием, и способ ее изготовления |
| US7145125B2 (en) | 2003-06-23 | 2006-12-05 | Advanced Optical Technologies, Llc | Integrating chamber cone light using LED sources |
| US20050048118A1 (en) * | 2003-07-25 | 2005-03-03 | Joan Cucala Escoi | Modified release venlafaxine hydrochloride tablets |
| WO2005042485A1 (en) * | 2003-10-30 | 2005-05-12 | Sk Chemicals, Co., Ltd. | Acid added salts of amlodipine |
| KR100841409B1 (ko) * | 2003-12-16 | 2008-06-25 | 에스케이케미칼주식회사 | 암로디핀 겐티세이트 염과 이의 제조방법 |
| US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
| WO2005089353A2 (en) * | 2004-03-16 | 2005-09-29 | Sepracor Inc. | (s)-amlodipine malate |
| DE602005025755D1 (de) | 2004-06-04 | 2011-02-17 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
| US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
| CN101035541B (zh) * | 2004-08-30 | 2012-05-30 | 柳署弘 | 溶解的udca在局灶缺血模型中的神经保护作用 |
| AU2005295541B2 (en) * | 2004-10-15 | 2011-02-17 | Seo Hong Yoo | Methods and compositions for reducing toxicity of a pharmaceutical compound |
| WO2006050165A2 (en) * | 2004-11-01 | 2006-05-11 | Seo Hong Yoo | Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis |
| WO2006056845A1 (en) * | 2004-11-23 | 2006-06-01 | Warner-Lambert Company Llc | 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia |
| WO2006059217A1 (en) * | 2004-12-01 | 2006-06-08 | Ranbaxy Laboratories Limited | Stable solid dosage forms of amlodipine besylate and processes for their preparation |
| WO2006070248A1 (en) * | 2004-12-28 | 2006-07-06 | Ranbaxy Laboratories Limited | Methods for the preparation of stable pharmaceutical solid dosage forms of atorvastatin and amlodipine |
| WO2006085208A2 (en) * | 2005-02-11 | 2006-08-17 | Ranbaxy Laboratories Limited | Stable solid dosage forms of amlodipine and benazepril |
| US20090298814A1 (en) * | 2005-06-07 | 2009-12-03 | Ramot At Tel Aviv Univeristy Ltd | Novel salts of conjugated psychotropic drugs and processes of preparing same |
| TWI405580B (zh) * | 2005-06-27 | 2013-08-21 | Sankyo Co | 含有血管收縮素ｉｉ接受器拮抗劑及鈣通道阻斷劑之醫藥調配物 |
| PT1797885E (pt) * | 2005-09-28 | 2008-05-20 | Teva Pharma | Combinações estáveis de besilato de amlodipina e cloridrato de benazepril |
| US8158146B2 (en) | 2005-09-28 | 2012-04-17 | Teva Pharmaceutical Industries Ltd. | Stable combinations of amlodipine besylate and benazepril hydrochloride |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| CA2627599A1 (en) | 2005-11-08 | 2007-05-18 | Ranbaxy Laboratories Limited | Process for (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt |
| US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| FR2894826B1 (fr) * | 2005-12-21 | 2010-10-22 | Servier Lab | Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur calcique et les compositions pharmaceutiques qui la contiennent |
| WO2008010223A2 (en) | 2006-07-17 | 2008-01-24 | Ramot At Tel Aviv University Ltd. | Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use in treating pain and other cns disorders |
| KR100795313B1 (ko) | 2006-09-05 | 2008-01-21 | 현대약품 주식회사 | 암로디핀 베실레이트를 포함하는 약학 조성물 |
| TWI399223B (zh) | 2006-09-15 | 2013-06-21 | Daiichi Sankyo Co Ltd | 奧美沙坦酯及氨氯地平之固體劑型 |
| US20080096863A1 (en) * | 2006-10-19 | 2008-04-24 | Torrent Pharmaceuticals Limited | Stable pharmaceutical compositions of calcium channel blocker and an ACE inhibitor |
| CN101167724B (zh) * | 2006-10-25 | 2012-08-22 | 北京华安佛医药研究中心有限公司 | 含有氨氯地平的药物组合物在制备治疗下尿路疾病药物中的用途 |
| ES2382009T3 (es) | 2006-12-01 | 2012-06-04 | Bristol-Myers Squibb Company | Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares |
| JP2011502953A (ja) * | 2006-12-21 | 2011-01-27 | ゼノポート，インコーポレーテッド | ジメチル置換されたレボドパジエステルのプロドラッグ、組成物及び使用方法 |
| CN101652131A (zh) | 2007-01-29 | 2010-02-17 | 韩兀制药株式会社 | N,n-二甲基亚氨基二碳亚氨酸二酰胺乙酸盐、其制备方法和包含其的药物组合物 |
| WO2008124121A1 (en) * | 2007-04-06 | 2008-10-16 | Scidose, Llc | Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters |
| WO2009032286A2 (en) | 2007-09-06 | 2009-03-12 | Nektar Therapeutics Al, Corporation | Oligomer-calcium channel blocker conjugates |
| US8143314B1 (en) * | 2007-09-13 | 2012-03-27 | Robert Carl Stover | Methods and formulations for treating ineffective or decreased esophageal motility |
| WO2009038396A2 (en) * | 2007-09-21 | 2009-03-26 | Hanall Pharmaceutical Company. Ltd | N,n-dimethyl imidodicarbonimidic diamide dicarboxylate, method for producing the same and pharmaceutical compositions comprising the same |
| BRPI0821455A2 (pt) | 2007-12-31 | 2015-06-16 | Lupin Ltd | Composições farmacêuticas de amlopidina e valsartan |
| WO2009101616A1 (en) | 2008-02-11 | 2009-08-20 | Ramot At Tel Aviv University Ltd. | Novel conjugates for treating neurodegenerative diseases and disorders |
| RU2359672C1 (ru) * | 2008-02-18 | 2009-06-27 | Зао "Биоком" | Твердая лекарственная форма, предназначенная для лечения артериальной гипертензии и стенокардии, и способ ее получения |
| CN101564536B (zh) * | 2008-04-21 | 2010-12-15 | 鲁南制药集团股份有限公司 | 一种治疗高血压的药物组合物缓控释制剂 |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| KR101892989B1 (ko) | 2008-06-27 | 2018-08-30 | 셀젠 카르 엘엘씨 | 헤테로아릴 화합물 및 이의 용도 |
| US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| US8399513B2 (en) | 2008-10-20 | 2013-03-19 | Xenoport, Inc. | Levodopa prodrug mesylate hydrate |
| US9290445B2 (en) * | 2008-10-20 | 2016-03-22 | Xenoport, Inc. | Methods of synthesizing a levodopa ester prodrug |
| US20110294860A1 (en) * | 2008-12-17 | 2011-12-01 | Medrx Co., Ltd. | Aqueous oral preparation of stable amlodipine |
| WO2010085014A1 (en) | 2009-01-23 | 2010-07-29 | Hanmi Pharm. Co., Ltd. | Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same |
| CA2789236C (en) * | 2009-11-09 | 2014-09-09 | Xenoport, Inc. | Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use |
| WO2011070579A1 (en) | 2009-12-09 | 2011-06-16 | Biolinerx Ltd. | Methods of improving cognitive functions |
| WO2011098971A1 (en) | 2010-02-12 | 2011-08-18 | Pfizer Inc. | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
| EP2539857A4 (en) | 2010-02-24 | 2013-07-24 | Univ Ramot | CRYSTALLINE FORMS OF TRI MESYLATE SALT OF PERPHENAZINE GABA AND METHOD OF MANUFACTURING THEREOF |
| WO2011117876A1 (en) | 2010-03-26 | 2011-09-29 | Fdc Limited | An improved process for the preparation of amlodipine free base and acid addition salts thereof |
| IT1400309B1 (it) * | 2010-05-10 | 2013-05-24 | Menarini Int Operations Lu Sa | Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso. |
| EP2425859A1 (en) | 2010-08-08 | 2012-03-07 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Olmesartan formulations |
| BR112013003388A2 (pt) * | 2010-08-10 | 2016-07-12 | Celgene Avilomics Res Inc | sal de besilato de um inibidor de btk |
| US8916610B2 (en) | 2010-09-22 | 2014-12-23 | Ramot At Tel-Aviv University Ltd. | Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same |
| TWI632134B (zh) | 2010-11-01 | 2018-08-11 | 阿維拉製藥公司 | 雜環化合物及其用途 |
| US9238629B2 (en) | 2010-11-01 | 2016-01-19 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| WO2012064706A1 (en) | 2010-11-10 | 2012-05-18 | Avila Therapeutics, Inc. | Mutant-selective egfr inhibitors and uses thereof |
| WO2012071524A1 (en) * | 2010-11-24 | 2012-05-31 | Ratiopharm Gmbh | Arylsulfonate salts of fingolimod and processes for preparation thereof |
| CA2853498A1 (en) | 2011-10-28 | 2013-05-02 | Celgene Avilomics Research, Inc. | Methods of treating a bruton's tyrosine kinase disease or disorder |
| RU2711077C9 (ru) | 2012-03-15 | 2020-08-11 | Селджен Кар Ллс | Соли ингибитора киназы рецептора эпидермального фактора роста |
| KR102081042B1 (ko) | 2012-03-15 | 2020-02-26 | 셀젠 카르 엘엘씨 | 상피 성장 인자 수용체 키나제 억제제의 고체 형태 |
| PL236001B1 (pl) | 2012-12-21 | 2020-11-30 | Adamed Spolka Z Ograniczona Odpowiedzialnoscia | Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję |
| US9126950B2 (en) | 2012-12-21 | 2015-09-08 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| ES2805359T3 (es) | 2013-02-08 | 2021-02-11 | Celgene Car Llc | Inhibidores de ERK y sus usos |
| WO2014122585A1 (en) | 2013-02-08 | 2014-08-14 | Wockhardt Limited | A stable pharmaceutical composition of amlodipine and benazepril or salts thereof |
| EP2986599A1 (en) | 2013-04-17 | 2016-02-24 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
| US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
| US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| US10005760B2 (en) | 2014-08-13 | 2018-06-26 | Celgene Car Llc | Forms and compositions of an ERK inhibitor |
| WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
| CN104529877A (zh) * | 2015-01-22 | 2015-04-22 | 华东理工常熟研究院有限公司 | 氨氯地平-癸酸离子液体及其制备方法和用途 |
| CN104523588A (zh) * | 2015-01-22 | 2015-04-22 | 华东理工常熟研究院有限公司 | 氨氯地平-硬脂酸离子液体及其制备方法和用途 |
| CN104610130A (zh) * | 2015-01-22 | 2015-05-13 | 华东理工常熟研究院有限公司 | 氨氯地平-棕榈酸离子液体及其制备方法和用途 |
| EP3334466B1 (en) | 2015-08-14 | 2020-05-13 | Endocyte, Inc. | Method of imaging with a chelating compound |
| US20180303811A1 (en) | 2015-10-23 | 2018-10-25 | Ftf Pharma Private Limited | Oral solution of dihydropyridine derivatives |
| CN105395495A (zh) * | 2015-11-30 | 2016-03-16 | 宜昌东阳光长江药业股份有限公司 | 一种含有苯磺酸氨氯地平的组合物及其制备方法 |
| EP3219309A1 (en) | 2016-03-17 | 2017-09-20 | K.H.S. Pharma Holding GmbH | Fixed dosed pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension |
| US20200316029A1 (en) | 2016-05-30 | 2020-10-08 | Boehringer Ingelheim International Gmbh | Fixed dose combination of telmisartan, hydrochlorothiazide and amlodipine |
| WO2018067959A1 (en) | 2016-10-07 | 2018-04-12 | Silvergate Pharmaceuticals, Inc. | Amlodipine formulations |
| US10350171B2 (en) | 2017-07-06 | 2019-07-16 | Dexcel Ltd. | Celecoxib and amlodipine formulation and method of making the same |
| EP3501502A1 (en) | 2017-12-20 | 2019-06-26 | Midas Pharma GmbH | Fixed dosed pharmaceutical compositions comprising amlodipine, ramipril and atorvastatin |
| CN112334134A (zh) | 2018-04-11 | 2021-02-05 | 希沃盖特制药公司 | 氨氯地平制剂 |
| AU2019285170A1 (en) | 2018-06-14 | 2021-01-28 | Astrazeneca Uk Limited | Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition |
| MX2021008533A (es) | 2019-01-18 | 2021-08-19 | Astrazeneca Ab | Inhibidores de la pcsk9 y metodos de uso de los mismos. |
| US11253474B1 (en) | 2021-02-01 | 2022-02-22 | Liqmeds Worldwide Limited | Pharmaceutical solution of amlodipine |
| EP4052695A1 (en) | 2021-03-05 | 2022-09-07 | Midas Pharma GmbH | Stable oral fixed-dose immediate release pharmaceutical compositions comprising amlodipine, atorvastatin and candesartan cilexetil |
| WO2023285646A1 (en) | 2021-07-15 | 2023-01-19 | Adamed Pharma S.A | A pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3816612A (en) * | 1967-03-23 | 1974-06-11 | Degussa | Process for the production of basically reacting pharmaceuticals |
| US4032637A (en) * | 1972-09-26 | 1977-06-28 | Sandoz Ltd. | Method of promoting sleep |
| US4177278A (en) * | 1977-04-05 | 1979-12-04 | Bayer Aktiengesellschaft | 2-Alkyleneaminodihydropyridines compounds, their production and their medicinal use |
| JPS5547656A (en) * | 1978-09-29 | 1980-04-04 | Dainippon Pharmaceut Co Ltd | 2-(2-substituted aminoethyl)-1,4-dihydropyridine derivative and its derivative |
| CS228917B2 (en) * | 1981-03-14 | 1984-05-14 | Pfizer | Method of preparing substituted derivatives of 1,4-dihydropyridine |
| DK161312C (da) * | 1982-03-11 | 1991-12-09 | Pfizer | Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden |
| ZA839187B (en) * | 1982-12-10 | 1984-07-25 | Ciba Geigy Ag | Amide compounds |
-
1986
- 1986-04-04 GB GB868608335A patent/GB8608335D0/en active Pending
-
1987
- 1987-03-18 LU LU86812A patent/LU86812A1/fr unknown
- 1987-03-30 DE DE19873710457 patent/DE3710457A1/de not_active Withdrawn
- 1987-03-30 CN CN87102493A patent/CN1023800C/zh not_active Expired - Lifetime
- 1987-03-31 DE DE8787302767T patent/DE3761485D1/de not_active Expired - Lifetime
- 1987-03-31 GB GB8707653A patent/GB2188630B/en not_active Expired - Lifetime
- 1987-03-31 AT AT87302767T patent/ATE49752T1/de not_active IP Right Cessation
- 1987-03-31 EP EP87302767A patent/EP0244944B1/en not_active Expired - Lifetime
- 1987-03-31 ES ES87302767T patent/ES2012803B3/es not_active Expired - Lifetime
- 1987-03-31 SE SE8701348A patent/SE463457B/sv not_active IP Right Cessation
- 1987-03-31 EG EG191/87A patent/EG18266A/xx active
- 1987-04-01 MX MX584787A patent/MX5847A/es unknown
- 1987-04-01 MY MYPI87000413A patent/MY101177A/en unknown
- 1987-04-02 YU YU580/87A patent/YU44801B/xx unknown
- 1987-04-02 PH PH35098A patent/PH24348A/en unknown
- 1987-04-02 AP APAP/P/1987/000060A patent/AP50A/en active
- 1987-04-02 IN IN281/DEL/87A patent/IN168414B/en unknown
- 1987-04-02 GR GR870525A patent/GR870525B/el unknown
- 1987-04-02 CS CS872363A patent/CS265237B2/cs not_active IP Right Cessation
- 1987-04-02 PT PT84611A patent/PT84611B/pt unknown
- 1987-04-02 CA CA000533732A patent/CA1321393C/en not_active Expired - Lifetime
- 1987-04-02 AR AR87307197A patent/AR242562A1/es active
- 1987-04-03 FR FR8704705A patent/FR2596758B1/fr not_active Expired
- 1987-04-03 IT IT19977/87A patent/IT1203853B/it active
- 1987-04-03 UA UA4202353A patent/UA6344A1/uk unknown
- 1987-04-03 NO NO871408A patent/NO172181C/no unknown
- 1987-04-03 FI FI871470A patent/FI85017C/fi not_active IP Right Cessation
- 1987-04-03 ES ES8700965A patent/ES2002599A6/es not_active Expired
- 1987-04-03 DK DK170187A patent/DK171708B1/da active IP Right Grant
- 1987-04-03 MA MA21175A patent/MA20938A1/fr unknown
- 1987-04-03 PL PL1987264982A patent/PL149532B1/pl unknown
- 1987-04-03 NL NL8700791A patent/NL8700791A/nl not_active Application Discontinuation
- 1987-04-03 BE BE8700349A patent/BE1000130A4/fr not_active IP Right Cessation
- 1987-04-03 IE IE86987A patent/IE59457B1/en not_active IP Right Cessation
- 1987-04-03 IL IL82101A patent/IL82101A/xx not_active IP Right Cessation
- 1987-04-03 NZ NZ219868A patent/NZ219868A/xx unknown
- 1987-04-03 DD DD87301485A patent/DD265142A5/de unknown
- 1987-04-03 ZA ZA872439A patent/ZA872439B/xx unknown
- 1987-04-03 JP JP62082787A patent/JPS62240660A/ja active Granted
- 1987-04-03 SU SU874202353A patent/SU1498388A3/ru active
- 1987-04-03 HU HU871450A patent/HU196962B/hu unknown
- 1987-04-04 KR KR1019870003209A patent/KR950006710B1/ko not_active Expired - Lifetime
-
1988
- 1988-10-13 US US07/256,938 patent/US4879303A/en not_active Expired - Lifetime
-
1990
- 1990-03-21 GR GR90400158T patent/GR3000394T3/el unknown
-
1991
- 1991-11-22 CZ CS19913539A patent/CZ289095B6/cs not_active IP Right Cessation
- 1991-11-22 SK SK3539-91A patent/SK278435B6/sk unknown
-
1992
- 1992-03-16 BG BG096073A patent/BG60698B2/xx unknown
- 1992-06-04 SG SG596/92A patent/SG59692G/en unknown
- 1992-10-01 HK HK760/92A patent/HK76092A/en not_active IP Right Cessation
-
1993
- 1993-05-14 CY CY1669A patent/CY1669A/xx unknown
-
1994
- 1994-07-26 EC EC1994001129A patent/ECSP941129A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU196962B (en) | Process for producing amlodipin-bezilate | |
| RU2241701C1 (ru) | Камзилат амлодипина, способ его получения и фармацевтическая композиция на его основе | |
| EP1391453B1 (en) | Pyroglutamic acid salt of amlodipine | |
| EP1499592A1 (en) | Amlodipine nicotinate and process for the preparation thereof | |
| KR950007228B1 (ko) | 암로디핀의 베실레이트염 | |
| US20040029931A1 (en) | Organic acid salt of amlodipine | |
| MXPA05001241A (es) | Sal acida organica de amilodipina. | |
| US20040029923A1 (en) | Organic acid salt of amlodipine | |
| KR100496436B1 (ko) | 암로디핀의 유기산염 | |
| SI8710580A8 (sl) | Postopek za pridobivanje benzolsulfonatne soli 3-etil-5-metil-2-(2-aminoetoksimetil)- 4-{2-klorofenil)-1.4-dihidro-6- metilpiridin-3.5-dikarboksilata | |
| KR100765464B1 (ko) | 암로디핀 말레이트를 포함하는 약제조성물 및 그 제조 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HU90 | Patent valid on 900628 |